Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Pipeline Review, H2 2016

Published: Dec, 2016 | Pages: 56 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Pipeline Review, H2 2016', provides in depth analysis on Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted pipeline therapeutics. 

The report provides comprehensive information on the Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: 
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7)
- The report reviews Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) Overview 6
Therapeutics Development 7
Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Products under Development by Stage of Development 7
Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Products under Development by Therapy Area 8
Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Products under Development by Indication 9
Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Pipeline Products Glance 10
Late Stage Products 10
Early Stage Products 11
Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Products under Development by Companies 12
Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Therapeutics Assessment 14
Assessment by Monotherapy/Combination Products 14
Assessment by Mechanism of Action 15
Assessment by Route of Administration 16
Assessment by Molecule Type 18
Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Companies Involved in Therapeutics Development 20
Aviara Pharmaceuticals Inc 20
Encycle Therapeutics 21
Genentech Inc 22
Protagonist Therapeutics Inc 23
Takeda Pharmaceutical Company Ltd 24
Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Drug Profiles 25
etrolizumab - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
PTG-100 - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
Small Molecule to Antagonize Integrin Alpha4 and Beta7 for Inflammatory Bowel Disease - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
Small Molecules to Antagonize Integrin Alpha 4 and Integrin Beta 7 for Crohn's Disease and Ulcerative Colitis - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
vedolizumab - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Dormant Projects 36
Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Discontinued Products 37
Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Featured News & Press Releases 38
Dec 09, 2016: GEMINI II & III Post-hoc Analysis Reports Clinical Benefits of Vedolizumab as Induction and Maintenance Therapy in Tumor Necrosis Factor-Naive Patients with Moderately to Severely Active Crohns Disease 38
Dec 08, 2016: Takeda Presents 17 Abstracts at the 2016 Advances in Inflammatory Bowel Diseases (AIBD) Annual Conference 39
Nov 24, 2016: Takeda's ENTYVIO (vedolizumab) receives positive reimburement recommendation from Common Drug Review for treatment of Crohns Disease 40
Nov 23, 2016: Takeda IBD Treatment ENTYVIO (vedolizumab) Receives Prestigious Prix Galien Canada Innovative Product Award 42
Oct 17, 2016: Takeda Presents Real-World Vedolizumab Data in Ulcerative Colitis and Crohn's Disease at 2016 American College of Gastroenterology (ACG) Annual Scientific Meeting 43
Oct 17, 2016: Takeda's Vedolizumab Demonstrated Robust Clinical Effectiveness and Safety in Inflammatory Bowel Disease in More Than 50 Real-World Studies 44
Oct 13, 2016: Scientists at NIH and Emory achieve sustained SIV remission in monkeys 45
Oct 13, 2016: Protagonist Therapeutics to Present Phase 1 Clinical and Preclinical Data on PTG-100 at UEG Week, Vienna 47
Oct 12, 2016: PROMETHEUS Anser VDZ Test Validated For Use in Inflammatory Bowel Disease Patients 47
Sep 28, 2016: Additional Interim Data Supporting Long-Term Use of Vedolizumab in Patients with Ulcerative Colitis and Crohn's Disease Published in Journal of Crohn's and Colitis 48
Sep 16, 2016: Favorable Benefit: Risk Profile for Vedolizumab as Induction and Maintenance Therapy in TNF-Na�ve or TNF-Failure Patients with Moderately to Severely Active Ulcerative Colitis Published in Clinical Gastroenterology and Hepatology 49
May 24, 2016: Takeda Presents Analyses From Vedolizumab Data in Ulcerative Colitis at 2016 Digestive Disease Week Annual Meeting 51
May 17, 2016: Protagonist Therapeutics to Present New Data on PTG-100 at Digestive Disease Week 2016 52
Mar 19, 2016: New Data Presented at European Crohn's and Colitis Organisation Scientific Meeting on Efficacy of Long-Term Vedolizumab Treatment 52
Jan 08, 2016: Protagonist Therapeutics Initiates Phase 1 Study with Oral Peptide PTG-100 53
Appendix 55
Methodology 55
Coverage 55
Secondary Research 55
Primary Research 55
Expert Panel Validation 55
Contact Us 55
Disclaimer 56

List of Tables

Number of Products under Development for, H2 2016 7
Number of Products under Development by Therapy Area, H2 2016 8
Number of Products under Development by Indication, H2 2016 9
Comparative Analysis by Late Stage Development, H2 2016 10
Comparative Analysis by Early Stage Products, H2 2016 11
Number of Products under Development by Companies, H2 2016 12
Products under Development by Companies, H2 2016 13
Assessment by Monotherapy/Combination Products, H2 2016 14
Number of Products by Stage and Mechanism of Action, H2 2016 15
Number of Products by Stage and Route of Administration, H2 2016 17
Number of Products by Stage and Molecule Type, H2 2016 19
Pipeline by Aviara Pharmaceuticals Inc, H2 2016 20
Pipeline by Encycle Therapeutics, H2 2016 21
Pipeline by Genentech Inc, H2 2016 22
Pipeline by Protagonist Therapeutics Inc, H2 2016 23
Pipeline by Takeda Pharmaceutical Company Ltd, H2 2016 24
Dormant Projects, H2 2016 36
Discontinued Products, H2 2016 37